Cargando…

Estimating health state utilities in hemophagocytic lymphohistiocytosis

BACKGROUND: Hemophagocyti.c lymphohistiocytosis (HLH) is a rare and severe disorder characterized by abnormal activation of the immune system. Primary HLH causes prolonged fever, spleen and liver enlargement, and organ dysfunction, usually in infancy and early childhood and is fatal if left untreate...

Descripción completa

Detalles Bibliográficos
Autores principales: Nafees, Beenish, Lloyd, Andrew, Dewilde, Sarah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817728/
https://www.ncbi.nlm.nih.gov/pubmed/33471193
http://dx.doi.org/10.1186/s41687-020-00276-9
_version_ 1783638700827082752
author Nafees, Beenish
Lloyd, Andrew
Dewilde, Sarah
author_facet Nafees, Beenish
Lloyd, Andrew
Dewilde, Sarah
author_sort Nafees, Beenish
collection PubMed
description BACKGROUND: Hemophagocyti.c lymphohistiocytosis (HLH) is a rare and severe disorder characterized by abnormal activation of the immune system. Primary HLH causes prolonged fever, spleen and liver enlargement, and organ dysfunction, usually in infancy and early childhood and is fatal if left untreated. As effective treatment options emerge, such as emapalumab-lzsg, Health Technology Assessment bodies around the world will assess them in terms of cost-effectiveness. This study was designed to estimate quality of life weights (utilities) for such analyses. METHODS: Vignettes were developed describing HLH treatment related health states. Health states included active HLH, HLH plus neurological symptoms, receiving chemotherapy, undergoing stem cell transplant (SCT), graft versus host disease (GVHD), cure and end of life care. The vignettes were based on information from in depth interviews with clinical specialists; and qualitative research with four parents of children with primary HLH aged between 1 and 18 years old. The vignettes were then assessed in time trade off (TTO) interviews with members of the UK general public in one on one face to face interviews with trained, experienced interviewers. Preference data were analysed using the generalised estimating equations framework. RESULTS: Detailed qualitative data captured the substantial burden of this disease for young children. One hundred participants completed the TTO interviews. The utility score for Active HLH was estimated as 0.32 (95% CI, 0.24 to 0.39). Values for other states were HLH plus neurological symptoms (0.27, 95%CI 0.18–0.35), receiving chemotherapy (0.26, 95%CI 0.17–0.34), undergoing SCT (0.18, 95%CI 0.07–0.28), GVHD (0.07, 95%CI -0.04-0.17), cure (0.72, 95%CI 0.67–0.77) and end of life care (− 0.17, 95%CI -0.27- -0.07). CONCLUSIONS: This study has estimated utility weights for seven different HLH related states which are based on detailed input from carers and physicians and have good face validity. There are few other options for collecting these data in an ultra-rare setting.
format Online
Article
Text
id pubmed-7817728
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-78177282021-01-25 Estimating health state utilities in hemophagocytic lymphohistiocytosis Nafees, Beenish Lloyd, Andrew Dewilde, Sarah J Patient Rep Outcomes Research BACKGROUND: Hemophagocyti.c lymphohistiocytosis (HLH) is a rare and severe disorder characterized by abnormal activation of the immune system. Primary HLH causes prolonged fever, spleen and liver enlargement, and organ dysfunction, usually in infancy and early childhood and is fatal if left untreated. As effective treatment options emerge, such as emapalumab-lzsg, Health Technology Assessment bodies around the world will assess them in terms of cost-effectiveness. This study was designed to estimate quality of life weights (utilities) for such analyses. METHODS: Vignettes were developed describing HLH treatment related health states. Health states included active HLH, HLH plus neurological symptoms, receiving chemotherapy, undergoing stem cell transplant (SCT), graft versus host disease (GVHD), cure and end of life care. The vignettes were based on information from in depth interviews with clinical specialists; and qualitative research with four parents of children with primary HLH aged between 1 and 18 years old. The vignettes were then assessed in time trade off (TTO) interviews with members of the UK general public in one on one face to face interviews with trained, experienced interviewers. Preference data were analysed using the generalised estimating equations framework. RESULTS: Detailed qualitative data captured the substantial burden of this disease for young children. One hundred participants completed the TTO interviews. The utility score for Active HLH was estimated as 0.32 (95% CI, 0.24 to 0.39). Values for other states were HLH plus neurological symptoms (0.27, 95%CI 0.18–0.35), receiving chemotherapy (0.26, 95%CI 0.17–0.34), undergoing SCT (0.18, 95%CI 0.07–0.28), GVHD (0.07, 95%CI -0.04-0.17), cure (0.72, 95%CI 0.67–0.77) and end of life care (− 0.17, 95%CI -0.27- -0.07). CONCLUSIONS: This study has estimated utility weights for seven different HLH related states which are based on detailed input from carers and physicians and have good face validity. There are few other options for collecting these data in an ultra-rare setting. Springer International Publishing 2021-01-20 /pmc/articles/PMC7817728/ /pubmed/33471193 http://dx.doi.org/10.1186/s41687-020-00276-9 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Research
Nafees, Beenish
Lloyd, Andrew
Dewilde, Sarah
Estimating health state utilities in hemophagocytic lymphohistiocytosis
title Estimating health state utilities in hemophagocytic lymphohistiocytosis
title_full Estimating health state utilities in hemophagocytic lymphohistiocytosis
title_fullStr Estimating health state utilities in hemophagocytic lymphohistiocytosis
title_full_unstemmed Estimating health state utilities in hemophagocytic lymphohistiocytosis
title_short Estimating health state utilities in hemophagocytic lymphohistiocytosis
title_sort estimating health state utilities in hemophagocytic lymphohistiocytosis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817728/
https://www.ncbi.nlm.nih.gov/pubmed/33471193
http://dx.doi.org/10.1186/s41687-020-00276-9
work_keys_str_mv AT nafeesbeenish estimatinghealthstateutilitiesinhemophagocyticlymphohistiocytosis
AT lloydandrew estimatinghealthstateutilitiesinhemophagocyticlymphohistiocytosis
AT dewildesarah estimatinghealthstateutilitiesinhemophagocyticlymphohistiocytosis